MedTrace Logo

Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL

NCT02656147 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-09-05

No results posted yet for this study

Summary

This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic γδT-cells in patients with high risk, relapsed CD19+ haematological malignancies.

Conditions

Interventions

BIOLOGICAL

Anti-CD19-CAR γδT

Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)

Sponsors & Collaborators

  • Beijing Doing Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Li gangyi, master · Beijing Doing Biomedical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2019-04-30
Completion
2020-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656147 on ClinicalTrials.gov